MAPK1 and allergic disease: The inhibition of overactive MAPKs by elevated CO2 levels in allergic reactions is of particular interest because MAPK/NF-κB-inhibiting drugs (e.g., lidocaine or p38 inhibitors) [129] and elevated CO2 levels are both effective in treating allergy symptoms.